VEGFA and renal cell adenocarcinoma: Overall, this highlights the need for highly selective inhibitors in order to reduce off‐target effects that result in toxicities, which collaterally limit tolerability of potentially clinical beneficial drugs, as seen with, for example, sorafenib in the treatment of either melanoma or renal cell cancer relative to either more selective BRAFV600 inhibitors (e.g. vemurafenib) for melanoma 24 or VEGF inhibitors (e.g., axitinib) in renal cell cancer 25.